Eloralintide Research Timeline: Discovery to Phase 3
A dated guide to the main Eloralintide evidence sources and how to interpret development stages without confusing them with product approval.
The Eloralintide research timeline includes receptor investigation, published early clinical studies, and the Phase 3 ENLIGHTEN program. Research status reviewed October 1, 2026. Development information can change, so use the linked primary sources when checking a later update.
This timeline summarizes evidence types and study milestones. It does not provide clinical-use instructions or transfer clinical findings to independently supplied research materials.
Eloralintide research milestones at a glance
| Evidence stage | Source to review | What the record contributes |
|---|---|---|
| Discovery and receptor investigation | Discovery publication | Experimental background for the compound |
| Phase 1 | Published proof-of-concept study | Early clinical study design and reported observations |
| Phase 2 | Published randomized trial | A larger controlled clinical investigation |
| Phase 3 | ENLIGHTEN-1 study listing | Registered late-stage study information |
| Combination development | September 30, 2026 Lilly announcement | A sponsor update on the separate EloraTZP program |
These entries are a reading map, not a claim that every study in the development program is listed here.
Discovery research: establish the experimental context
Begin by identifying the study material and the questions investigated. The discovery paper is the appropriate starting point for understanding why later researchers examined the molecule. For the receptor vocabulary behind this work, see Eloralintide mechanism and amylin receptors.
Keep publication dates separate from experiment dates. A paper may describe work performed years earlier, and a later publication date does not necessarily indicate a later stage of experimentation.
Phase 1: read the design before the headline
The published Phase 1 report describes a 12-week, randomized, placebo-controlled study examining safety, tolerability, pharmacokinetics, and pharmacodynamics. Its observations concern that study population and protocol.
When reviewing an early study, record the participant population, duration, comparison groups, and measured endpoints. Check which conclusions are directly supported and which are proposals for further investigation. Do not convert the study's methods into instructions for a commercial RUO product.
Phase 2: a different study, a separate evidence record
The 48-week Phase 2 publication reports a randomized, double-blind, placebo-controlled investigation enrolling 263 participants at 46 US research centers.
Retain the paper as a separate record from the Phase 1 report. Different populations, follow-up periods, and methods mean that a simple side-by-side headline comparison can miss important context. In a literature summary, clearly label whether a statement comes from the abstract, full results, or supplementary methods.
Phase 3: the ENLIGHTEN program
Lilly's ENLIGHTEN-1 listing identifies a Phase III study of Eloralintide in adults with obesity or overweight without type 2 diabetes. The registry identifier shown is NCT07321886.
A trial listing describes a study; it should not be presented as a completed results paper. Check the phase, status, record update, and any results posting separately. Phase 3 development also should not be described as regulatory approval.
Keep EloraTZP on a separate timeline
Combination development adds another branch to the literature. A milestone for a combination should not automatically be assigned to Eloralintide alone, or vice versa. Our Eloralintide and EloraTZP guide explains the program names and the source distinctions.
For an ongoing research tracker, use separate columns for single-agent studies, combination studies, publications, and sponsor announcements. This prevents an anticipated milestone from appearing as a completed event.
A repeatable way to check future updates
- Open the original publication, registry, or sponsor release.
- Record its identifier and the date you checked it.
- Distinguish actual events from planned milestones.
- Note whether methods and results are available.
- Preserve previous entries when making a dated correction.
For the compound introduction, return to what Eloralintide is. For material-specific questions, consult the Eloralintide product listing and laboratory evaluation guide; neither substitutes for a pharmaceutical clinical-trial record.
Frequently asked questions
Is a registered study the same as published results?
No. A registry can describe the planned study and its status before results are available. Treat the design record and the results report as separate sources.
Do later development stages change RUO product restrictions?
No. A commercial material's intended-use restrictions and documentation remain separate from pharmaceutical development milestones.
For laboratory research use only. Not for human or animal consumption or administration.